Movement Alert｜GENSCRIPT BIO Rises 5.07% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY as Interim Results Review Approaches

Market Focus08-06 09:51

On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.

On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing nearly 50% year-over-year growth and sustaining strong commercial momentum. The sales data was provided by collaboration partner Janssen Biotech under their cooperation and license agreement.

Additionally, the CXO sector has rallied broadly in recent sessions, buoyed by WuXi AppTec's H1 results showing revenue growth of approximately 39% and non-GAAP net profit growth of approximately 89%, lifting sector sentiment. GENSCRIPT BIO benefits from both industry tailwinds and its own fundamental catalysts. The company's board is scheduled to convene on August 15 to review and approve interim results for H1 and consider an interim dividend.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126653090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126653090","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.07% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY as Interim Results Review Approaches","media":"Market Focus","content":"<p><p>On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.</p><p>On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing nearly 50% year-over-year growth and sustaining strong commercial momentum. The sales data was provided by collaboration partner Janssen Biotech under their cooperation and license agreement.</p><p>Additionally, the CXO sector has rallied broadly in recent sessions, buoyed by WuXi AppTec's H1 results showing revenue growth of approximately 39% and non-GAAP net profit growth of approximately 89%, lifting sector sentiment. GENSCRIPT BIO benefits from both industry tailwinds and its own fundamental catalysts. The company's board is scheduled to convene on August 15 to review and approve interim results for H1 and consider an interim dividend.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.07% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY as Interim Results Review Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.07% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY as Interim Results Review Approaches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.</p><p>On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing nearly 50% year-over-year growth and sustaining strong commercial momentum. The sales data was provided by collaboration partner Janssen Biotech under their cooperation and license agreement.</p><p>Additionally, the CXO sector has rallied broadly in recent sessions, buoyed by WuXi AppTec's H1 results showing revenue growth of approximately 39% and non-GAAP net profit growth of approximately 89%, lifting sector sentiment. GENSCRIPT BIO benefits from both industry tailwinds and its own fundamental catalysts. The company's board is scheduled to convene on August 15 to review and approve interim results for H1 and consider an interim dividend.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1126653090","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126653090","pubTimestamp":1785981111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.On the news front, the company's associate Legend Biotech disclosed that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨5.07%，随着中期业绩审查临近，CARVYKTI第二季度销售额同比飙升近50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing nearly 50% year-over-year growth and sustaining strong commercial momentum. The sales data was provided by collaboration partner Janssen Biotech under their cooperation and license agreement.Additionally, the CXO sector has rallied broadly in recent sessions, buoyed by WuXi AppTec's H1 results showing revenue growth of approximately 39% and non-GAAP net profit growth of approximately 89%, lifting sector sentiment. GENSCRIPT BIO benefits from both industry tailwinds and its own fundamental catalysts. The company's board is scheduled to convene on August 15 to review and approve interim results for H1 and consider an interim dividend.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126653090","isCrawlerRequest":true}